Iterum Therapeutics (ITRM) PT Lowered to $8 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ITRM Hot Sheet
Price: $0.03 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
RBC Capital analyst Gregory Renza lowered the price target on Iterum Therapeutics (NASDAQ: ITRM) to $8.00 (from $10.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Citi Upgrades Technogym SpA (TGYM:IM) (TCCHF) to Buy
- Avis Budget Group (CAR) PT Lowered to $125 at Susquehanna
- Arm Holdings (ARM) PT Lowered to $215 at HSBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
